No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Buy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350
Express News | HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $9 Price Target
Buy Rating for Ovid Therapeutics Based on Promising Drug Trials and Strategic Partnerships
TD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)
Strong Buy: Ovid Therapeutics' Promising Pipeline and Financial Stability
Ovid Therapeutics | 10-Q: Quarterly report
loading...
No Data